Suppliers / Chongqing Huapont Pharmaceutical

Chongqing Huapont Pharmaceutical

United States Updated 9 July 2026

Chongqing Huapont Pharmaceutical is an API manufacturer based in United States. It holds 17 active US drug master files across a filed portfolio of 15 molecules.

17
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Bendamustine US FDA 2
Isotretinoin US FDA 2
Acitretin US FDA 1
Acrivastine US FDA 1
Dapsone US FDA 1
Dimethyl Fumarate US FDA 1
Fluticasone Propionate US FDA 1
Levocetirizine US FDA 1
Linezolid US FDA 1
Moxifloxacin US FDA 1
Show all 15 molecules on file
Naftifine US FDA 1
Paricalcitol US FDA 1
Roflumilast US FDA 1
Ruxolitinib US FDA 1
Tretinoin US FDA 1

Also appears on these molecule pages

Comparing suppliers?

Choose your molecules and target markets. Chongqing Huapont Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability